Dynamic contrast-enhanced CT in patients treated with sorafenib and erlotinib for non-small cell lung cancer: a new method of monitoring treatment?
Objective We investigated the feasibility of serial dynamic contrast-enhanced computed tomography (DCE-CT) in patients with advanced/metastatic non-small cell lung cancer (NSCLC) receiving anti-angiogenic (sorafenib) and anti-EGFR (erlotinib) treatment, and correlated tumour blood flow (BF) with tre...
Gespeichert in:
| Veröffentlicht in: | European radiology 2010-12, Vol.20 (12), p.2890-2898 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2898 |
|---|---|
| container_issue | 12 |
| container_start_page | 2890 |
| container_title | European radiology |
| container_volume | 20 |
| creator | Lind, Joline S. W. Meijerink, Martijn R. Dingemans, Anne-Marie C. van Kuijk, Cornelis Öllers, Michel C. de Ruysscher, Dirk Postmus, Pieter E. Smit, Egbert F. |
| description | Objective
We investigated the feasibility of serial dynamic contrast-enhanced computed tomography (DCE-CT) in patients with advanced/metastatic non-small cell lung cancer (NSCLC) receiving anti-angiogenic (sorafenib) and anti-EGFR (erlotinib) treatment, and correlated tumour blood flow (BF) with treatment outcome.
Methods
DCE-CTs were performed at baseline and 3 and 6 weeks after starting treatment. Tumour BF, calculated with the maximum slope method, and percentage change were measured in 23 patients (14 male; median age 59 years). Tumour BF was compared at baseline and weeks 3 and 6; the relation with RECIST/Crabb response and progression-free survival (PFS) was assessed.
Results
Mean tumour perfusion decreased from 39.2 ml/100 g/min at baseline to 15.1 ml/100 g/min at week 3 (
p
|
| doi_str_mv | 10.1007/s00330-010-1869-5 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2978316</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>764496431</sourcerecordid><originalsourceid>FETCH-LOGICAL-c468t-95fe2a4d70499a22adc6e33ba0b48aeeb1658a07daf5d531245478fab090030a3</originalsourceid><addsrcrecordid>eNp1kU2PFCEQhonRuOPqD_BiiBdPaNHQDXjQmPEz2cTLeibV3fQOm24YgXGzv8M_LO2s60fiBVLFU29R9RLymMNzDqBeZAAhgAEHxnVnWHuHbLgUDeOg5V2yASM0U8bIE_Ig50sAMFyq--Skga5pldAb8v3tdcDFD3SIoSTMhbmwwzC4kW7PqQ90j8W7UDItyWGp6StfdjTHhJMLvqcYRurSHItfoykmGmJgecF5poOrx3wIF3RYJdNLijS4K7q4sosjjRNdYvAlJl-Rn_pLbfX6Ibk34Zzdo5v7lHx5_-58-5Gdff7wafvmjA2y04WZdnINylGBNAabBsehc0L0CL3U6FzPu1YjqBGndmwFb2QrlZ6wB1P3BihOyauj7v7QL24c3LqB2e6TXzBd24je_v0S_M5exG-2MUoL3lWBZzcCKX49uFzs4vM6NAYXD9mqTkrTScEr-fQf8jIeUqjTWQ2qFUIrUSF-hIYUc05uuv0KB7sabo-GW1jjarhta82TP2e4rfjlcAWaI5D365pd-t35_6o_AMZHuVI</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>807533873</pqid></control><display><type>article</type><title>Dynamic contrast-enhanced CT in patients treated with sorafenib and erlotinib for non-small cell lung cancer: a new method of monitoring treatment?</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>Lind, Joline S. W. ; Meijerink, Martijn R. ; Dingemans, Anne-Marie C. ; van Kuijk, Cornelis ; Öllers, Michel C. ; de Ruysscher, Dirk ; Postmus, Pieter E. ; Smit, Egbert F.</creator><creatorcontrib>Lind, Joline S. W. ; Meijerink, Martijn R. ; Dingemans, Anne-Marie C. ; van Kuijk, Cornelis ; Öllers, Michel C. ; de Ruysscher, Dirk ; Postmus, Pieter E. ; Smit, Egbert F.</creatorcontrib><description>Objective
We investigated the feasibility of serial dynamic contrast-enhanced computed tomography (DCE-CT) in patients with advanced/metastatic non-small cell lung cancer (NSCLC) receiving anti-angiogenic (sorafenib) and anti-EGFR (erlotinib) treatment, and correlated tumour blood flow (BF) with treatment outcome.
Methods
DCE-CTs were performed at baseline and 3 and 6 weeks after starting treatment. Tumour BF, calculated with the maximum slope method, and percentage change were measured in 23 patients (14 male; median age 59 years). Tumour BF was compared at baseline and weeks 3 and 6; the relation with RECIST/Crabb response and progression-free survival (PFS) was assessed.
Results
Mean tumour perfusion decreased from 39.2 ml/100 g/min at baseline to 15.1 ml/100 g/min at week 3 (
p
< 0.001) and 9.4 ml/100 g/min at week 6 (
p
< 0.001). Tumour perfusion was lower in RECIST and Crabb responders versus non-responders at week 3 (4.2 versus 17.7 ml/100 g/min,
p
= 0.03) and week 6 (0 versus 13.4 ml/100 g/min,
p
= 0.04). Patients with a decrease larger than the median at week 6 tended to have a longer PFS (7.1 versus 5.7 months,
p
= 0.06).
Conclusion
Serial DCE-CTs are feasible in patients with NSCLC and demonstrated a significant decrease in tumour BF following sorafenib/erlotinib therapy. Early changes in tumour BF correlated with objective response and showed a trend towards longer PFS.</description><identifier>ISSN: 0938-7994</identifier><identifier>EISSN: 1432-1084</identifier><identifier>DOI: 10.1007/s00330-010-1869-5</identifier><identifier>PMID: 20625738</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer-Verlag</publisher><subject><![CDATA[Antineoplastic Combined Chemotherapy Protocols - administration & dosage ; Benzenesulfonates - administration & dosage ; Carcinoma, Non-Small-Cell Lung - diagnostic imaging ; Carcinoma, Non-Small-Cell Lung - drug therapy ; Carcinoma, Non-Small-Cell Lung - secondary ; Contrast Media ; Diagnostic Radiology ; Erlotinib Hydrochloride ; Female ; Humans ; Imaging ; Internal Medicine ; Interventional Radiology ; Iohexol - analogs & derivatives ; Lung Neoplasms - diagnostic imaging ; Lung Neoplasms - drug therapy ; Lung Neoplasms - secondary ; Male ; Medicine ; Medicine & Public Health ; Neuroradiology ; Niacinamide - analogs & derivatives ; Oncology ; Phenylurea Compounds ; Prognosis ; Pyridines - administration & dosage ; Quinazolines - administration & dosage ; Radiographic Image Enhancement - methods ; Radiology ; Reproducibility of Results ; Sensitivity and Specificity ; Sorafenib ; Tomography, X-Ray Computed - methods ; Treatment Outcome ; Ultrasound]]></subject><ispartof>European radiology, 2010-12, Vol.20 (12), p.2890-2898</ispartof><rights>The Author(s) 2010</rights><rights>European Society of Radiology 2010</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c468t-95fe2a4d70499a22adc6e33ba0b48aeeb1658a07daf5d531245478fab090030a3</citedby><cites>FETCH-LOGICAL-c468t-95fe2a4d70499a22adc6e33ba0b48aeeb1658a07daf5d531245478fab090030a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00330-010-1869-5$$EPDF$$P50$$Gspringer$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00330-010-1869-5$$EHTML$$P50$$Gspringer$$Hfree_for_read</linktohtml><link.rule.ids>230,314,776,780,881,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20625738$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lind, Joline S. W.</creatorcontrib><creatorcontrib>Meijerink, Martijn R.</creatorcontrib><creatorcontrib>Dingemans, Anne-Marie C.</creatorcontrib><creatorcontrib>van Kuijk, Cornelis</creatorcontrib><creatorcontrib>Öllers, Michel C.</creatorcontrib><creatorcontrib>de Ruysscher, Dirk</creatorcontrib><creatorcontrib>Postmus, Pieter E.</creatorcontrib><creatorcontrib>Smit, Egbert F.</creatorcontrib><title>Dynamic contrast-enhanced CT in patients treated with sorafenib and erlotinib for non-small cell lung cancer: a new method of monitoring treatment?</title><title>European radiology</title><addtitle>Eur Radiol</addtitle><addtitle>Eur Radiol</addtitle><description>Objective
We investigated the feasibility of serial dynamic contrast-enhanced computed tomography (DCE-CT) in patients with advanced/metastatic non-small cell lung cancer (NSCLC) receiving anti-angiogenic (sorafenib) and anti-EGFR (erlotinib) treatment, and correlated tumour blood flow (BF) with treatment outcome.
Methods
DCE-CTs were performed at baseline and 3 and 6 weeks after starting treatment. Tumour BF, calculated with the maximum slope method, and percentage change were measured in 23 patients (14 male; median age 59 years). Tumour BF was compared at baseline and weeks 3 and 6; the relation with RECIST/Crabb response and progression-free survival (PFS) was assessed.
Results
Mean tumour perfusion decreased from 39.2 ml/100 g/min at baseline to 15.1 ml/100 g/min at week 3 (
p
< 0.001) and 9.4 ml/100 g/min at week 6 (
p
< 0.001). Tumour perfusion was lower in RECIST and Crabb responders versus non-responders at week 3 (4.2 versus 17.7 ml/100 g/min,
p
= 0.03) and week 6 (0 versus 13.4 ml/100 g/min,
p
= 0.04). Patients with a decrease larger than the median at week 6 tended to have a longer PFS (7.1 versus 5.7 months,
p
= 0.06).
Conclusion
Serial DCE-CTs are feasible in patients with NSCLC and demonstrated a significant decrease in tumour BF following sorafenib/erlotinib therapy. Early changes in tumour BF correlated with objective response and showed a trend towards longer PFS.</description><subject>Antineoplastic Combined Chemotherapy Protocols - administration & dosage</subject><subject>Benzenesulfonates - administration & dosage</subject><subject>Carcinoma, Non-Small-Cell Lung - diagnostic imaging</subject><subject>Carcinoma, Non-Small-Cell Lung - drug therapy</subject><subject>Carcinoma, Non-Small-Cell Lung - secondary</subject><subject>Contrast Media</subject><subject>Diagnostic Radiology</subject><subject>Erlotinib Hydrochloride</subject><subject>Female</subject><subject>Humans</subject><subject>Imaging</subject><subject>Internal Medicine</subject><subject>Interventional Radiology</subject><subject>Iohexol - analogs & derivatives</subject><subject>Lung Neoplasms - diagnostic imaging</subject><subject>Lung Neoplasms - drug therapy</subject><subject>Lung Neoplasms - secondary</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Neuroradiology</subject><subject>Niacinamide - analogs & derivatives</subject><subject>Oncology</subject><subject>Phenylurea Compounds</subject><subject>Prognosis</subject><subject>Pyridines - administration & dosage</subject><subject>Quinazolines - administration & dosage</subject><subject>Radiographic Image Enhancement - methods</subject><subject>Radiology</subject><subject>Reproducibility of Results</subject><subject>Sensitivity and Specificity</subject><subject>Sorafenib</subject><subject>Tomography, X-Ray Computed - methods</subject><subject>Treatment Outcome</subject><subject>Ultrasound</subject><issn>0938-7994</issn><issn>1432-1084</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp1kU2PFCEQhonRuOPqD_BiiBdPaNHQDXjQmPEz2cTLeibV3fQOm24YgXGzv8M_LO2s60fiBVLFU29R9RLymMNzDqBeZAAhgAEHxnVnWHuHbLgUDeOg5V2yASM0U8bIE_Ig50sAMFyq--Skga5pldAb8v3tdcDFD3SIoSTMhbmwwzC4kW7PqQ90j8W7UDItyWGp6StfdjTHhJMLvqcYRurSHItfoykmGmJgecF5poOrx3wIF3RYJdNLijS4K7q4sosjjRNdYvAlJl-Rn_pLbfX6Ibk34Zzdo5v7lHx5_-58-5Gdff7wafvmjA2y04WZdnINylGBNAabBsehc0L0CL3U6FzPu1YjqBGndmwFb2QrlZ6wB1P3BihOyauj7v7QL24c3LqB2e6TXzBd24je_v0S_M5exG-2MUoL3lWBZzcCKX49uFzs4vM6NAYXD9mqTkrTScEr-fQf8jIeUqjTWQ2qFUIrUSF-hIYUc05uuv0KB7sabo-GW1jjarhta82TP2e4rfjlcAWaI5D365pd-t35_6o_AMZHuVI</recordid><startdate>20101201</startdate><enddate>20101201</enddate><creator>Lind, Joline S. W.</creator><creator>Meijerink, Martijn R.</creator><creator>Dingemans, Anne-Marie C.</creator><creator>van Kuijk, Cornelis</creator><creator>Öllers, Michel C.</creator><creator>de Ruysscher, Dirk</creator><creator>Postmus, Pieter E.</creator><creator>Smit, Egbert F.</creator><general>Springer-Verlag</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QO</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20101201</creationdate><title>Dynamic contrast-enhanced CT in patients treated with sorafenib and erlotinib for non-small cell lung cancer: a new method of monitoring treatment?</title><author>Lind, Joline S. W. ; Meijerink, Martijn R. ; Dingemans, Anne-Marie C. ; van Kuijk, Cornelis ; Öllers, Michel C. ; de Ruysscher, Dirk ; Postmus, Pieter E. ; Smit, Egbert F.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c468t-95fe2a4d70499a22adc6e33ba0b48aeeb1658a07daf5d531245478fab090030a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Antineoplastic Combined Chemotherapy Protocols - administration & dosage</topic><topic>Benzenesulfonates - administration & dosage</topic><topic>Carcinoma, Non-Small-Cell Lung - diagnostic imaging</topic><topic>Carcinoma, Non-Small-Cell Lung - drug therapy</topic><topic>Carcinoma, Non-Small-Cell Lung - secondary</topic><topic>Contrast Media</topic><topic>Diagnostic Radiology</topic><topic>Erlotinib Hydrochloride</topic><topic>Female</topic><topic>Humans</topic><topic>Imaging</topic><topic>Internal Medicine</topic><topic>Interventional Radiology</topic><topic>Iohexol - analogs & derivatives</topic><topic>Lung Neoplasms - diagnostic imaging</topic><topic>Lung Neoplasms - drug therapy</topic><topic>Lung Neoplasms - secondary</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Neuroradiology</topic><topic>Niacinamide - analogs & derivatives</topic><topic>Oncology</topic><topic>Phenylurea Compounds</topic><topic>Prognosis</topic><topic>Pyridines - administration & dosage</topic><topic>Quinazolines - administration & dosage</topic><topic>Radiographic Image Enhancement - methods</topic><topic>Radiology</topic><topic>Reproducibility of Results</topic><topic>Sensitivity and Specificity</topic><topic>Sorafenib</topic><topic>Tomography, X-Ray Computed - methods</topic><topic>Treatment Outcome</topic><topic>Ultrasound</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lind, Joline S. W.</creatorcontrib><creatorcontrib>Meijerink, Martijn R.</creatorcontrib><creatorcontrib>Dingemans, Anne-Marie C.</creatorcontrib><creatorcontrib>van Kuijk, Cornelis</creatorcontrib><creatorcontrib>Öllers, Michel C.</creatorcontrib><creatorcontrib>de Ruysscher, Dirk</creatorcontrib><creatorcontrib>Postmus, Pieter E.</creatorcontrib><creatorcontrib>Smit, Egbert F.</creatorcontrib><collection>Springer Nature OA/Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>European radiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lind, Joline S. W.</au><au>Meijerink, Martijn R.</au><au>Dingemans, Anne-Marie C.</au><au>van Kuijk, Cornelis</au><au>Öllers, Michel C.</au><au>de Ruysscher, Dirk</au><au>Postmus, Pieter E.</au><au>Smit, Egbert F.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Dynamic contrast-enhanced CT in patients treated with sorafenib and erlotinib for non-small cell lung cancer: a new method of monitoring treatment?</atitle><jtitle>European radiology</jtitle><stitle>Eur Radiol</stitle><addtitle>Eur Radiol</addtitle><date>2010-12-01</date><risdate>2010</risdate><volume>20</volume><issue>12</issue><spage>2890</spage><epage>2898</epage><pages>2890-2898</pages><issn>0938-7994</issn><eissn>1432-1084</eissn><abstract>Objective
We investigated the feasibility of serial dynamic contrast-enhanced computed tomography (DCE-CT) in patients with advanced/metastatic non-small cell lung cancer (NSCLC) receiving anti-angiogenic (sorafenib) and anti-EGFR (erlotinib) treatment, and correlated tumour blood flow (BF) with treatment outcome.
Methods
DCE-CTs were performed at baseline and 3 and 6 weeks after starting treatment. Tumour BF, calculated with the maximum slope method, and percentage change were measured in 23 patients (14 male; median age 59 years). Tumour BF was compared at baseline and weeks 3 and 6; the relation with RECIST/Crabb response and progression-free survival (PFS) was assessed.
Results
Mean tumour perfusion decreased from 39.2 ml/100 g/min at baseline to 15.1 ml/100 g/min at week 3 (
p
< 0.001) and 9.4 ml/100 g/min at week 6 (
p
< 0.001). Tumour perfusion was lower in RECIST and Crabb responders versus non-responders at week 3 (4.2 versus 17.7 ml/100 g/min,
p
= 0.03) and week 6 (0 versus 13.4 ml/100 g/min,
p
= 0.04). Patients with a decrease larger than the median at week 6 tended to have a longer PFS (7.1 versus 5.7 months,
p
= 0.06).
Conclusion
Serial DCE-CTs are feasible in patients with NSCLC and demonstrated a significant decrease in tumour BF following sorafenib/erlotinib therapy. Early changes in tumour BF correlated with objective response and showed a trend towards longer PFS.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer-Verlag</pub><pmid>20625738</pmid><doi>10.1007/s00330-010-1869-5</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0938-7994 |
| ispartof | European radiology, 2010-12, Vol.20 (12), p.2890-2898 |
| issn | 0938-7994 1432-1084 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2978316 |
| source | MEDLINE; SpringerLink Journals |
| subjects | Antineoplastic Combined Chemotherapy Protocols - administration & dosage Benzenesulfonates - administration & dosage Carcinoma, Non-Small-Cell Lung - diagnostic imaging Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - secondary Contrast Media Diagnostic Radiology Erlotinib Hydrochloride Female Humans Imaging Internal Medicine Interventional Radiology Iohexol - analogs & derivatives Lung Neoplasms - diagnostic imaging Lung Neoplasms - drug therapy Lung Neoplasms - secondary Male Medicine Medicine & Public Health Neuroradiology Niacinamide - analogs & derivatives Oncology Phenylurea Compounds Prognosis Pyridines - administration & dosage Quinazolines - administration & dosage Radiographic Image Enhancement - methods Radiology Reproducibility of Results Sensitivity and Specificity Sorafenib Tomography, X-Ray Computed - methods Treatment Outcome Ultrasound |
| title | Dynamic contrast-enhanced CT in patients treated with sorafenib and erlotinib for non-small cell lung cancer: a new method of monitoring treatment? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T20%3A13%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Dynamic%20contrast-enhanced%20CT%20in%20patients%20treated%20with%20sorafenib%20and%20erlotinib%20for%20non-small%20cell%20lung%20cancer:%20a%20new%20method%20of%20monitoring%20treatment?&rft.jtitle=European%20radiology&rft.au=Lind,%20Joline%20S.%20W.&rft.date=2010-12-01&rft.volume=20&rft.issue=12&rft.spage=2890&rft.epage=2898&rft.pages=2890-2898&rft.issn=0938-7994&rft.eissn=1432-1084&rft_id=info:doi/10.1007/s00330-010-1869-5&rft_dat=%3Cproquest_pubme%3E764496431%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=807533873&rft_id=info:pmid/20625738&rfr_iscdi=true |